Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success

Awaiting Word From AbbVie On Option Exercise

 
• By Mandy Jackson

The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

Woman applying eye drops on light background, closeup
Reproxalap's rapid efficacy may be differentiating in dry eye disease • Source: Shutterstock

More from Clinical Trials

More from R&D